Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | Director · Chief Executive Officer | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,485 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Gift · Disposed 528 · Balance 35,485 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 43,803 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 43,803 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2026 Filed Aug 20, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 528 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000138 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,485 Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $179.66 | $0.00 |
DisclosureSEC source: 0001100682-26-000132 · form4.xml · derivative · entry 4 Girshick Birgit · CIK 0001732091 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,500 shares Expires 2030-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,500 | $279.90 | $1,819,350.00 |
DisclosureSEC source: 0001100682-26-000132 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,013 F1 · shares: This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 3, 2025. Read SEC document |
| August 11, 2026 Filed Aug 13, 2026 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 6,500 | $179.66 | $1,167,790.00 |
DisclosureSEC source: 0001100682-26-000132 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000107 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Revocable Trust Disclosed balance after: 43,803 F1 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 3,386 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 3,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000107 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,013 F1 · shares: Reflects the exempt transfer pursuant to Rule 16a-13 of 3,386 shares held by the reporting person to a revocable trust controlled by the reporting person. Read SEC document |
| May 31, 2026 Filed Jun 2, 2026 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 378 | $180.71 | $68,308.38 |
DisclosureSEC source: 0001100682-26-000093 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,399 Read SEC document |
| May 30, 2026 Filed Jun 2, 2026 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,204 | $180.71 | $217,574.84 |
DisclosureSEC source: 0001100682-26-000093 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,777 Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:35 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 9,961 | $180.71 | $1,800,052.31 |
DisclosureSEC source: 0001100682-26-000093 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,981 F1 · shares: Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 242 | $156.73 | $37,928.66 |
DisclosureSEC source: 0001100682-26-000079 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,020 Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 376 | $160.30 | $60,272.80 |
DisclosureSEC source: 0001100682-26-000079 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,262 Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000028 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Indirect · Revocable Trust Disclosed balance after: 40,417 F1 · balance_after: Includes shares that were previously reported as directly held, which are now correctly reported as indirectly held. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 3,061 | $211.68 | $647,952.48 |
DisclosureSEC source: 0001100682-26-000010 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,913 Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 21:42 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000010 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,974 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 20:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 283 | $135.63 | $38,383.29 |
DisclosureSEC source: 0001127602-25-016544 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,944 Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:52 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 12,239 | $135.63 | $1,659,975.57 |
DisclosureSEC source: 0001127602-25-016544 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,227 F1 · shares: Unvested restricted stock units vest annually on: May 30, 2026; May 30, 2027; May 30, 2028; May 30, 2029. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 117 | $138.65 | $16,222.05 |
DisclosureSEC source: 0001127602-25-015895 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,988 Read SEC document |
| May 27, 2025 Filed May 29, 2025 20:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 242 | $136.73 | $33,088.66 |
DisclosureSEC source: 0001127602-25-015895 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,105 Read SEC document |
| May 26, 2025 Filed May 29, 2025 20:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 281 | $136.73 | $38,421.13 |
DisclosureSEC source: 0001127602-25-015895 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,347 Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 430 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006850 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,628 Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | PurchaseCommon Stock | 1,514 | $164.63 | $249,249.82 |
DisclosureSEC source: 0001127602-25-006251 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,058 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,025 | $165.57 | $169,709.25 |
DisclosureSEC source: 0001127602-25-002714 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,544 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:22 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 4,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-002714 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,569 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 8,722 | $208.44 Strike: $208.44 | $1,818,013.68 |
DisclosureSEC source: 0001127602-24-017674 · form4.xml · derivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,722 Underlying: Common Stock · 8,722 shares Expires 2034-05-31 F2 · shares: Stock options vest as follows: 2,180 on May 31, 2025, 2,181 on May 31, 2026, 2,180 on May 31, 2027, and 2,181 on May 31, 2028. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 3,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017674 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,512 F1 · shares: Unvested restricted stock units vest as follows: 959 on May 31, 2025, 960 on May 31, 2026, 959 on May 31, 2027, and 960 on May 31, 2028. Read SEC document |
| May 29, 2024 Filed May 29, 2024 21:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 216 | $214.51 | $46,334.16 |
DisclosureSEC source: 0001127602-24-016818 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,674 Read SEC document |
| May 28, 2024 Filed May 28, 2024 21:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 132 | $217.21 | $28,671.72 |
DisclosureSEC source: 0001127602-24-016724 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,890 Read SEC document |
| May 27, 2024 Filed May 28, 2024 21:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 242 | $217.21 | $52,564.82 |
DisclosureSEC source: 0001127602-24-016724 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,022 Read SEC document |
| May 26, 2024 Filed May 28, 2024 21:25 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 376 | $217.21 | $81,670.96 |
DisclosureSEC source: 0001127602-24-016724 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,264 Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 23:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 424 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-005439 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,691 Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 00:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,159 | $220.28 | $255,304.52 |
DisclosureSEC source: 0001127602-24-002840 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,115 Read SEC document |
| January 29, 2024 Filed Feb 1, 2024 00:14 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 3,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002840 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,274 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 21:52 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,135 | $220.28 | $250,017.80 |
DisclosureSEC source: 0001127602-24-011096 · form4a.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,064 Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 21:52 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 3,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011096 · form4a.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,199 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,916 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-24-001215 · form4.xml · derivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,916 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The transaction was executed as a net exercise, in which no shares were purchased or sold in the open market. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 4,590 | $215.19 | $987,722.10 |
DisclosureSEC source: 0001127602-24-001215 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,775 Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:09 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 5,916 | $215.19 | $1,273,064.04 |
DisclosureSEC source: 0001127602-24-001215 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2024 Filed Jan 31, 2024 22:34 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,916 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-24-002811 · form4a.xml · derivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,916 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The transaction was executed as a net exercise, in which no shares were purchased or sold in the open market. Read SEC document |
| January 10, 2024 Filed Jan 31, 2024 22:34 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 4,617 | $213.14 | $984,067.38 |
DisclosureSEC source: 0001127602-24-002811 · form4a.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,748 Read SEC document |
| January 10, 2024 Filed Jan 31, 2024 22:34 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 5,916 | $144.67 | $855,867.72 |
DisclosureSEC source: 0001127602-24-002811 · form4a.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2023 Filed Nov 21, 2023 22:07 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | PurchaseCommon Stock | 1,322 | $187.82 | $248,298.04 |
DisclosureSEC source: 0001127602-23-028148 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,449 F1 · balance_after: The total in column 5 reflects the ownership as of the date of the transaction. Read SEC document |
| May 29, 2023 Filed May 31, 2023 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 216 | $194.12 | $41,929.92 |
DisclosureSEC source: 0001127602-23-017133 · form4.xml · nonDerivative · entry 4 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,477 Read SEC document |
| May 28, 2023 Filed May 31, 2023 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 132 | $194.12 | $25,623.84 |
DisclosureSEC source: 0001127602-23-017133 · form4.xml · nonDerivative · entry 3 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,693 Read SEC document |
| May 27, 2023 Filed May 31, 2023 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 242 | $194.12 | $46,977.04 |
DisclosureSEC source: 0001127602-23-017133 · form4.xml · nonDerivative · entry 2 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,825 Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 9,145 | $194.12 Strike: $194.12 | $1,775,227.40 |
DisclosureSEC source: 0001127602-23-017133 · form4.xml · derivative · entry 5 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,145 Underlying: Common Stock · 9,145 shares Expires 2033-05-26 F2 · shares: Stock Options vest as follows: 2,286 on May 26, 2024, 2,286 on May 26, 2025, 2,286 on May 26, 2026 and 2,287 on May 26, 2027. Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 3,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017133 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,067 F1 · shares: Restricted Stock Units vest as follows: 953 on May 26, 2024, 953 on May 26, 2025, 953 on May 26, 2026 and 953 on May 26, 2027. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 21:16 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-009447 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,255 Read SEC document |
| February 22, 2023 Filed Feb 22, 2023 21:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 308 | $243.60 | $75,028.80 |
DisclosureSEC source: 0001127602-23-006456 · form4.xml · nonDerivative · entry 1 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,730 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 3,205 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-23-005905 · form4.xml · derivative · entry 12 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,205 shares Expires 2023-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 502 | $256.48 | $128,750.85 |
DisclosureSEC source: 0001127602-23-005905 · form4.xml · nonDerivative · entry 11 Girshick Birgit · CIK 0001732091 · Corporate Executive VP & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,038 F1 · kind: This sale occurred pursuant to a 10b5-1 Trading Plan. F8 · price: This transaction was executed in multiple trades at prices ranging from $256.21 to $257.015. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.